Advanced Cancer Patients' and Their Primary Caregivers' Willingness to Communicate About Advance Care Planning (ACP)

NCT ID: NCT05426330

Last Updated: 2022-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-04

Study Completion Date

2024-10-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Advanced care planning (ACP) is a major component of end-of-life care. Advanced care planning aims to (1) establish treatment and care options in the event that continuing cancer treatment is more risky than beneficial (e.g., participating in a clinical trial testing a new treatment; continuing supportive care only) and (2) establish possible treatment limitations in the event that a medical complication threatens the patient's survival without the patient's expressed wishes (e.g., transfer to an intensive care unit; resuscitation). However, cancer patients still rarely engage with their physician(s) and family in a discussion about ACP. The primary objective of the project is to conduct a cross-sectional, observational study of the willingness of advanced cancer patients and their primary caregivers to communicate about ACP with each other and with the physician(s); and their agreement/disagreement with these respective willingness. The secondary objective of the project is to assess the medical, psychological and relational factors associated with these willingness. This study will involve 300 consecutive patient- primary caregiver-physician(s) triads. For each patient and their primary caregiver, an in-depth assessment of their willingness to communicate about ACP with each other and with the physician(s) will be conducted using specific scales. The medical, psychological and relational characteristics of the included patients and their primary caregiver will also be assessed using validated questionnaires. Results of this study will enable to propose innovative interventions likely to optimize the establishment of an ACP for numerous advanced cancer patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Advanced care planning (ACP) is a major component of end-of-life care. Advanced care planning aims to (1) establish treatment and care options in the event that continuing cancer treatment is more risky than beneficial (e.g., participating in a clinical trial testing a new treatment; continuing supportive care only) and (2) establish possible treatment limitations in the event that a medical complication threatens the patient's survival without the patient's expressed wishes (e.g., transfer to an intensive care unit; resuscitation). ACP aims to ensure that the patient receives care consistent with their personal values, life goals, and preferences. Nowadays, ACP is conceived as an iterative process of communication between patients, their families, and caregivers. However, cancer patients still rarely engage with their physician(s) and family in a discussion about ACP.

There is a gap between the recommendations that communication take place between patients, their families and physician(s) regarding end-of-life care planning, and the application of this recommendation in clinical practice. This gap threatens the quality of life care as well as the adjustment of their caregivers to this phase of the disease and the grief that follows. A thorough and rigorous study of the reasons for this discrepancy has become an essential issue for the oncology of tomorrow.

No studies have quantified the respective willingness of cancer patients and their primary caregivers to communicate about ACP with each other and with their physician(s). No studies have quantified the agreement/disagreement of these patients and their primary caregivers on this issue. No study has assessed the medical, psychological, and relational factors associated with these respective willingness and agreements/disagreements.

This is a cross-sectional observational study. On a weekly basis, the list of eligible patients having a consultation at the Institut Jules Bordet in the medical oncology, hematology, surgery or radiotherapy departments will be provided by the Institute's IT department. An audit of the patients' medical records will be performed by the evaluator. This check will ensure that the patient meets the study's eligibility criteria.

Each patient will be personally contacted by telephone by an evaluator to introduce the study and solicit their participation. During this contact, the patient will identify and provide, if desired, the contact information for their primary caregiver and the physician they designate as their primary decision-maker in the treatment and care of their cancer condition.

A psycho-oncologist evaluator will conduct the assessment for all the patients, their primary caregiver and their physician. This assessment is based on an integrative model of medical, psychological and relational factors associated with the willingness of patients and their relatives to communicate about the patient's ACP. This model has allowed the development of case report forms with different questionnaires. Informed consent forms will be provided by the evaluator, due to the sensitivity of the topics addressed. The questionnaires of the patient, their primary caregiver and their physician will be administered within one month of the first contact with the patient. A simultaneous evaluation will be conducted with patients and primary caregivers. The time difference between the questionnaires of the three protagonists involved in the study will not exceed 72 hours. The completion of the questionnaire will be assisted, in person or if necessary remotely, before the consultation. The survey will be administered using the REDCAP software.

The recruitment of patients, their primary caregiver and their physician will be done consecutively. This recruitment will continue until 300 patient - primary caregiver - physician triads are included in the study. The socio-demographic and medical information of the subjects for whom this evaluation could not be performed, as well as the reasons for this non-evaluation, will be recorded and archived in the study results.

This is the first study to address in a observational manner the willingness of the patient and their primary caregiver to communicate about ACP, their agreement/disagreement with these respective willingness, and the associated medical and relational psychological factors. The Institut Jules Bordet provides a framework for conducting a study, the results of which will allow optimization of the process of establishing an ACP. This optimization will improve the quality of life of these patients and their families. Conducting this study will provide suggestions for interventions that may optimize the establishment of a ACP for many cancer patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The eligibility criteria for primary caregivers are as follows:

* Have been identified by the patient as the person who supports them the most with their cancer condition
* Be competent
* Speak French
* Be over 18 years of age
* Have given written informed consent to participate in the study


* Have been designated by the patient as the physician with whom they wish to make major decisions in terms of treatment planning and/or therapeutic limitations
* Speak French
* Have given written informed consent to participate in the study

Exclusion Criteria

* Not being competent (defined according to Appelbaum et al. (1988) as the ability to understand, reason and communicate)
* Have a poor command of the French language
* Already have a therapeutic limitation status, limited to supportive care (BSC status).
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fonds Gaston Ithier

UNKNOWN

Sponsor Role collaborator

Université Libre de Bruxelles

OTHER

Sponsor Role collaborator

Association Jules Bordet

UNKNOWN

Sponsor Role collaborator

Jules Bordet Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Jules Bordet

Brussels, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yves Libert, Ph.D

Role: CONTACT

003225413415

Lisa Choucroun, M.A.

Role: CONTACT

0032492314421

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yves Libert, Ph.D.

Role: primary

003225413415

Lisa Choucroun, M.A.

Role: backup

0032492314421

References

Explore related publications, articles, or registry entries linked to this study.

Appelbaum PS, Grisso T. Assessing patients' capacities to consent to treatment. N Engl J Med. 1988 Dec 22;319(25):1635-8. doi: 10.1056/NEJM198812223192504.

Reference Type BACKGROUND
PMID: 3200278 (View on PubMed)

Bhatt VR. Understanding patients' values and priorities in selecting cancer treatments: Developing a therapy preference scale. J Geriatr Oncol. 2019 Sep;10(5):677-679. doi: 10.1016/j.jgo.2018.11.005. Epub 2018 Nov 27. No abstract available.

Reference Type BACKGROUND
PMID: 30501985 (View on PubMed)

Bredart A, Beaudeau A, Young T, Moura De Alberquerque Melo H, Arraras JI, Friend L, Schmidt H, Tomaszewski KA, Bergenmar M, Anota A, Costantini A, Marchal F, Tomaszewska IM, Vassiliou V, Chie WC, Hureaux J, Conroy T, Ramage J, Bonnetain F, Kulis D, Aaronson NK; EORTC Quality of Life Group. The European organization for research and treatment of cancer - satisfaction with cancer care questionnaire: revision and extended application development. Psychooncology. 2017 Mar;26(3):400-404. doi: 10.1002/pon.4127. Epub 2016 Apr 13. No abstract available.

Reference Type BACKGROUND
PMID: 27546090 (View on PubMed)

Christensen JF, Flexas A, Calabrese M, Gut NK, Gomila A. Moral judgment reloaded: a moral dilemma validation study. Front Psychol. 2014 Jul 1;5:607. doi: 10.3389/fpsyg.2014.00607. eCollection 2014.

Reference Type BACKGROUND
PMID: 25071621 (View on PubMed)

Colquitt JA, LePine JA, Noe RA. Toward an integrative theory of training motivation: a meta-analytic path analysis of 20 years of research. J Appl Psychol. 2000 Oct;85(5):678-707. doi: 10.1037/0021-9010.85.5.678.

Reference Type BACKGROUND
PMID: 11055143 (View on PubMed)

Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. Can J Nurs Res. 1997 Fall;29(3):21-43.

Reference Type BACKGROUND
PMID: 9505581 (View on PubMed)

Epstein RM, Duberstein PR, Fenton JJ, Fiscella K, Hoerger M, Tancredi DJ, Xing G, Gramling R, Mohile S, Franks P, Kaesberg P, Plumb S, Cipri CS, Street RL Jr, Shields CG, Back AL, Butow P, Walczak A, Tattersall M, Venuti A, Sullivan P, Robinson M, Hoh B, Lewis L, Kravitz RL. Effect of a Patient-Centered Communication Intervention on Oncologist-Patient Communication, Quality of Life, and Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical Trial. JAMA Oncol. 2017 Jan 1;3(1):92-100. doi: 10.1001/jamaoncol.2016.4373.

Reference Type BACKGROUND
PMID: 27612178 (View on PubMed)

Finkelstein EA, Baid D, Cheung YB, Schweitzer ME, Malhotra C, Volpp K, Kanesvaran R, Lee LH, Dent RA, Ng Chau Hsien M, Bin Harunal Rashid MF, Somasundaram N. Hope, bias and survival expectations of advanced cancer patients: A cross-sectional study. Psychooncology. 2021 May;30(5):780-788. doi: 10.1002/pon.5675. Epub 2021 Apr 1.

Reference Type BACKGROUND
PMID: 33739561 (View on PubMed)

Freeston, M. H., Rhéaume, J., Letarte, H., Dugas, M. J., & Ladouceur, R. (1994). Why do people worry? Personality and Individual Differences, 17(6), 791-802. https://doi.org/10.1016/0191-8869(94)90048-5

Reference Type BACKGROUND

Fried TR, O'Leary JR. Using the experiences of bereaved caregivers to inform patient- and caregiver-centered advance care planning. J Gen Intern Med. 2008 Oct;23(10):1602-7. doi: 10.1007/s11606-008-0748-0. Epub 2008 Jul 30.

Reference Type BACKGROUND
PMID: 18665427 (View on PubMed)

Pautex S, Vayne-Bossert P, Bernard M, Beauverd M, Cantin B, Mazzocato C, Thollet C, Bollondi-Pauly C, Ducloux D, Herrmann F, Escher M. Validation of the French Version of the Edmonton Symptom Assessment System. J Pain Symptom Manage. 2017 Nov;54(5):721-726.e1. doi: 10.1016/j.jpainsymman.2017.07.032. Epub 2017 Jul 25.

Reference Type BACKGROUND
PMID: 28751077 (View on PubMed)

Razavi, D., Delvaux, N., Farvacques, C., & Robaye, E. (1989). Validation de la version française du HADS dans une population de patients cancéreux hospitalisés [Validation of the French version of the Hospital Anxiety and Depression Scale (HADS) in a population of hospitalized cancer patients]. Revue de Psychologie Appliquée, 39(4), 295-307.

Reference Type BACKGROUND

Rose JH, O'Toole EE, Dawson NV, Lawrence R, Gurley D, Thomas C, Hamel MB, Cohen HJ. Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Clin Oncol. 2004 Dec 15;22(24):4907-17. doi: 10.1200/JCO.2004.06.050. Epub 2004 Nov 1.

Reference Type BACKGROUND
PMID: 15520054 (View on PubMed)

Sudore RL, Lum HD, You JJ, Hanson LC, Meier DE, Pantilat SZ, Matlock DD, Rietjens JAC, Korfage IJ, Ritchie CS, Kutner JS, Teno JM, Thomas J, McMahan RD, Heyland DK. Defining Advance Care Planning for Adults: A Consensus Definition From a Multidisciplinary Delphi Panel. J Pain Symptom Manage. 2017 May;53(5):821-832.e1. doi: 10.1016/j.jpainsymman.2016.12.331. Epub 2017 Jan 3.

Reference Type BACKGROUND
PMID: 28062339 (View on PubMed)

Temel JS, Greer JA, Admane S, Solis J, Cashavelly BJ, Doherty S, Heist R, Pirl WF. Code status documentation in the outpatient electronic medical records of patients with metastatic cancer. J Gen Intern Med. 2010 Feb;25(2):150-3. doi: 10.1007/s11606-009-1161-z. Epub 2009 Nov 6.

Reference Type BACKGROUND
PMID: 19894078 (View on PubMed)

Yennurajalingam S, Rodrigues LF, Shamieh OM, Tricou C, Filbet M, Naing K, Ramaswamy A, Perez-Cruz PE, Bautista MJS, Bunge S, Muckaden MA, Fakrooden S, Sewram V, Tejedor AN, Rao SS, Williams JL, Liu DD, Park M, Lu Z, Cantu H, Hui D, Reddy SK, Bruera E. Decisional control preferences among patients with advanced cancer: An international multicenter cross-sectional survey. Palliat Med. 2018 Apr;32(4):870-880. doi: 10.1177/0269216317747442. Epub 2017 Dec 13.

Reference Type BACKGROUND
PMID: 29235415 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CE3353

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Responses Study
NCT04445896 COMPLETED
UC Health Care Planning Study
NCT04012749 COMPLETED NA
Cancer End Of Life Evaluation
NCT01545921 TERMINATED NA
Care Planning Framework in Advanced Cancer (ABC123)
NCT05408507 ACTIVE_NOT_RECRUITING NA